Out-of-pocket and catastrophic expenditure on treatment of haemophilia by Indian families

Haemophilia

Volumn 20, Issue 3, 2014, Pages 382-387

  Dharmarajan, S ^a   Phadnis, S ^a   Gund, P ^a   Kar, A ^a  

^a UNIVERSITY OF PUNE   (India)

Author keywords

Economics; Haemophilia; India; Out of pocket expenditure

Indexed keywords

BLOOD CLOTTING FACTOR CONCENTRATE;

ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; FOLLOW UP; HEALTH CARE COST; HEMOPHILIA A; HOUSEHOLD; HUMAN; INCOME; INDIA; INDIAN; PRIORITY JOURNAL; ECONOMICS; FAMILY SIZE; FEMALE; HEMORRHAGE; MALE; PATHOPHYSIOLOGY; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA;

FAMILY CHARACTERISTICS; FEMALE; HEALTH EXPENDITURES; HEMOPHILIA A; HEMORRHAGE; HUMANS; INDIA; MALE; QUESTIONNAIRES;

EID: 84898914859     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12324     Document Type: Article

References (14)

1. Gringeri A, Mantovani L, Scalone L, Mannucci M. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358-63.
2. Bohn RL, Aledort LM, Putnam KG, Ewenstein BM, Mogun H, Avorn J. The economic impact of factor VIII inhibitors in patients with haemophilia. Haemophilia 2004; 10: 63-8.
3. Farrugia A, Cassar J, Kimber MC et al. Treatment for life for severe haemophilia A- A cost-utility model for prophylaxis vs. on-demand treatment. Haemophilia 2013; 19: e228-38.
4. Fischer K, van der Bom JG, Molho P et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia 2002; 8: 745-52.
5. Skinner MW. WFH: closing the global gap-achieving optimal care. Haemophilia 2012; 18: 1-12.
6. Report on the Annual Global Survey 2011. World Federation of Haemophilia, 2013. Available at http://www1.wfh.org/publications/files/pdf-1488.pdf. Accessed August 10, 2013.
7. Bohn RL, Avorn J, Glynn RJ, Choodnovskiy I, Haschemeyer R, Aledort LM. Prophylactic use of factor VIII: an economic evaluation. Thromb Haemost 1998; 79: 932-7.
8. Globe DR, Curtis RG, Koerper MA, for the HUGS Steering Committee. Utilization of care in haemophilia: a resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS). Haemophilia 2004; 10: 63-70.
9. Nerich V, Tissot E, Faradji A et al. Cost-of-illness study of severe haemophilia A and B in five French haemophilia treatment centres. Pharm World Sci 2008; 30: 287-92.
10. Guh S, Grosse SD, McAlister S, Kessler CM, Soucie JM. Health care expenditures for Medicaid-covered males with haemophilia in the United States, 2008. Haemophilia 2012; 18: 276-83.
11. Dharmarajan S, Gund P, Phadnis S, Lohade S, Lalwani A, Kar A. Treatment decisions and usage of clotting factor concentrate by a cohort of Indian haemophilia patients. Haemophilia 2012; 18: e27-9.
12. Household consumer expenditure in India 2007-08. National Sample Survey Organisation. Ministry of Statistics and Program Implementation, 2010. Available at http://164.100.34.62/index.php/catalog/15. Accessed August 10, 2013.
13. Association of Haemophilia Clinic Directors of Canada. Haemophilia and vWDClinical Practice Guidelines - Management Haemophilia and von Willebrand's disease: 2. Management, 2nd edn. Available at http://ahcdc.ca/index.php/membership/practice-guidelines/86-hemophilia-and-vwd-clinical-practice-guidelines-management. Accessed August 10, 2013.
14. Xu K, Aguilar A, Carrin G et al. Distribution of health payments and catastrophic expenditures Methodology. Discussion Paper Number 2. World Health Organization, 2005. Available at http://www.who.int/health_financing/documents/dp_e_05_2-distribution_of_health_payments.pdf. Accessed August 10, 2013.